Company: MDCXW
Filing Date: 2025-06-13
Form Type: PRE 14A
Source: 0001062993-25-011673
Chunk: 70

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-13
Form: PRE 14A
Chunk 70
---
     
 compensation 
 earnings     
 ($)          | All Other    
 Compensation 
 ($)          | Total Compensation 
                ($) |
| Dr. Larry Kaiser     |      60,000 | -           |       30,257 | -            | -            | -            |             90,257 |
| Robert J. Ciaruffoli |      75,000 | -           |       30,257 | -            | -            | -            |            105,257 |
| Frank Lavelle        |      60,000 | -           |       30,257 | -            | -            | -            |             90,257 |
| William L. Ashton    |      50,000 | -           |       30,257 | -            | -            | -            |             80,257 |
| Barry Fishman        |      60,000 | -           |       30,257 | -            | -            | -            |             90,257 |
| Dr. Sara R. May(2)   |      30,000 | -           |       76,051 | -            | -            | -            |            106,051 |

(1)All non-executive directors were paid $50,000 annually, in quarterly installments, as compensation for Board membership in 2024. In addition, committee Chairs received an annual compensation of $10,000, other than the Chair of the Audit Committee, who received $15,000, and Mr. Ciaruffoli, as the lead director, who received an additional $10,000 per annum.

(2)Dr. Sara R. May joined the Board in June 2024.

Directors' Service Contracts

There are no arrangements or understandings between us, on the one hand, and any of our directors, on the other hand, providing for benefits upon termination of their service as directors of our company.

Clawback Policy

The Board adopted a clawback policy (the "Clawback Policy") in compliance with applicable SEC and Nasdaq requirements. The Clawback Policy requires the Company to recoup any erroneously awarded incentive-based compensation received by certain executives, including each named executive officer, in the event the Company is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the federal securities laws. The Clawback Policy generally applies to all incentive-based compensation received by a covered executive during the three completed fiscal years immediately preceding